Last 30 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Beam Therapeutics Inc.'s quarterly P/E stands at 3.0x.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -35.14 | 2.97 | — | — | — | — | — | — | — | 3.93 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 20.72 | 6.37 | 64.17 | 51.23 | 57.50 | 17.08 | 35.37 | 40.96 | 91.07 | 1.78 | 27.64 | 30.29 | 22.85 |
| — | -62.7% | +81.4% | +25.1% | -36.9% | +859.5% | +28.0% | +35.2% | +298.5% | -94.8% | -47.9% | -25.8% | -80.4% | |
| P/B Ratio | 2.27 | 2.35 | 2.58 | 1.66 | 1.53 | 2.80 | 2.55 | 2.26 | 2.95 | 2.29 | 2.44 | 3.00 | 2.91 |
| — | -16.1% | +1.0% | -26.6% | -48.2% | +22.1% | +4.6% | -24.8% | +1.7% | -39.2% | -48.0% | -11.6% | -38.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | 4.28 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 3.60 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 2.71 | — | — | — | — | — | — | — | 3.74 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Beam Therapeutics Inc.'s operating margin was -15.3% in Q4 2025, up 1292.3 pp QoQ and up 317.4 pp YoY. This marks the 4th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -1084.7% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 248.5% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.0% | 352.4% | -1031.9% | -1102.0% | -1222.8% | -237.4% | -560.6% | 100.0% | -1044.6% | 55.7% | -481.9% | -385.2% | -311.6% |
| — | +248.5% | -84.1% | -1202.0% | -17.1% | -526.2% | -16.3% | +126.0% | -235.2% | +116.8% | -9.6% | -10.8% | +53.9% | |
| Operating Margin | -274.6% | -15.3% | -1307.6% | -1419.2% | -1596.9% | -332.7% | -746.4% | -891.1% | -1405.3% | 42.0% | -629.7% | -507.8% | -408.7% |
| — | +95.4% | -75.2% | -59.3% | -13.6% | -891.8% | -18.5% | -75.5% | -243.9% | +109.5% | -9.0% | -3.2% | +54.8% | |
| Net Margin | -57.2% | 214.1% | -1162.4% | -1208.3% | -1462.8% | -300.5% | -677.5% | -773.5% | -1331.6% | 45.2% | -558.9% | -411.5% | -398.5% |
| — | +171.2% | -71.6% | -56.2% | -9.9% | -765.4% | -21.2% | -88.0% | -234.2% | +123.6% | +19.4% | +4.8% | +51.5% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.1% | 22.2% | -11.2% | -9.4% | -11.8% | -11.9% | -11.8% | -10.3% | -10.4% | 16.2% | -12.1% | -10.5% | -12.9% |
| — | +287.0% | +4.7% | +8.5% | -13.0% | -173.0% | +2.7% | +2.1% | +19.3% | +406.3% | +16.5% | -19.1% | -54.4% | |
| ROA | -6.2% | 17.5% | -8.3% | -7.2% | -8.5% | -7.9% | -7.9% | -6.9% | -7.0% | 10.4% | -7.3% | -6.2% | -7.2% |
| — | +320.3% | -5.0% | -3.0% | -21.5% | -176.5% | -9.4% | -12.7% | +3.0% | +464.5% | +8.2% | -23.0% | -52.6% | |
| ROIC | -33.6% | -1.3% | -10.8% | -10.8% | -13.1% | -11.2% | -11.0% | -10.3% | -10.3% | 13.3% | -10.5% | -10.6% | -10.8% |
| — | +88.0% | +2.4% | -4.1% | -26.8% | -184.6% | -4.8% | +2.1% | +4.8% | +240.5% | -11.0% | -19.9% | -4.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 171.4% YoY to 13.09x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.16 | 0.15 | 0.14 | 0.22 | 0.20 | 0.19 | 0.18 | 0.18 | 0.22 | 0.22 | 0.23 |
| — | -43.4% | -23.5% | -23.6% | -23.5% | +25.1% | -7.6% | -10.4% | -20.6% | -27.9% | -9.5% | -2.7% | +28.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 1.25 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 13.09 | 13.09 | 6.02 | 6.75 | 8.81 | 4.82 | 5.69 | 5.81 | 5.99 | 5.89 | 4.72 | 5.22 | 4.92 |
| — | +171.4% | +5.8% | +16.3% | +47.1% | -18.1% | +20.6% | +11.1% | +21.7% | +20.5% | +1.6% | -6.0% | -13.1% | |
| Quick Ratio | 13.09 | 13.09 | 6.02 | 6.75 | 8.81 | 4.82 | 5.69 | 5.81 | 5.99 | 5.89 | 4.72 | 5.22 | 4.92 |
| — | +171.4% | +5.8% | +16.3% | +47.1% | -18.1% | +20.6% | +11.1% | +21.7% | +20.5% | +1.6% | -6.0% | -13.1% | |
| Interest Coverage | -8.77 | -1.64 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonBeam Therapeutics Inc.'s current P/E is -35.1x. The average P/E over the last 1 quarters is 3.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Beam Therapeutics Inc.'s current operating margin is -274.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Beam Therapeutics Inc.'s business trajectory between earnings reports.